Our data suggest that HGF, c-MET amplification, and EGFR T790M mutation can upregulate PD-L1 expression and promote immune escape capability in NSCLC, and that the relative regulatory mechanisms of PD-L1 expression among three subtypes may be vary. Here, EGFR is linked to non-small cell lung carcinoma.